Beleodaq for Peripheral T-Cell Lymphoma – Detail

( Last Updated : October 24, 2018)

Generic Name:

Belinostat

Project Status:

Withdrawn

Manufacturer:

Servier Canada Inc.

Brand Name:

Beleodaq

Project Line:

Reimbursement Review

Project Number:

PC0139-000

Details

Tumour Type:

Lymphoma

Indications:

Peripheral T-Cell Lymphoma (PTCL)

Funding Request:

For the treatment of patients with relapsed or refractory PTCL

Review Status:

Withdrawn

Pre Noc Submission:

Yes

Sponsor:

Servier Canada Inc.

Submission Date:

June 29, 2018

Submission Deemed Complete:

July 9, 2018

Prioritization Requested:

Not Requested

Stakeholder Input Deadline ‡:

July 16, 2018

Clarification:

Servier Canada Inc. has notified pCODR that the Category 2 submission requirements for the pre NOC submission of Belinostat (Beleodaq) for Peripheral T-Cell Lymphoma (PTCL) cannot be met at this time. As per pCODR Procedures C3.1.6, the pCODR program has stopped the review.

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.